A5001672602- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Cancer Immunotherapy and Biomarkers
- CNS Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Cancer survivorship and care
- Blood disorders and treatments
- Immune Cell Function and Interaction
- Multiple Myeloma Research and Treatments
- Cancer Treatment and Pharmacology
- Acute Myeloid Leukemia Research
- Lung Cancer Treatments and Mutations
- Mycobacterium research and diagnosis
- Anesthesia and Pain Management
- Chemical Reactions and Isotopes
- Immunodeficiency and Autoimmune Disorders
- Mesenchymal stem cell research
- Colorectal Cancer Treatments and Studies
- Nutrition and Health in Aging
- Pathogenesis and Treatment of Hiccups
- Hematopoietic Stem Cell Transplantation
- Neutropenia and Cancer Infections
- Platelet Disorders and Treatments
National Medical and Surgical Center named after N.I. Pirogov
2010-2025
ORCID
2020
Ministry of Health of the Russian Federation
2018
Aim. To assess efficacy of netupitant / palonosetron with dexamethasone for chemotherapy‑induced nausea and vomiting in 20 patients multiple myeloma who underwent autologous hematopoietic stem cell transplantation. Materials methods. The inclusion criteria were aged ≥18 years a diagnosis myeloma, eligible transplantation favorable response (according to the International Myeloma working Group after induction therapy). Netupitant was administered at dose 1 capsule (300 mg netupitant; 0.5...
Background: Immunotherapy with checkpoint inhibitors (anti-PD-1) is highly effective in relapsed/refractory (R/R) classical Hodgkin Lymphoma (cHL) and leads to more than 70% overall response rate. However, long-term progression-free survival rate not sufficient. Consolidation ASCT after anti-PD-1 could be a very promising option even among previously chemorefractory patients. Nevertheless, there enough experience about the safety feasibility of context possible immune-related adverse events...
Aim. To estimate the long-term outcome of programmed treatment classical Hodgkin's lymphoma (cHL) including high-dose chemotherapy (HDCT) and autologous hematopoietic stem cell transplantation (auto-HSCT) as well effect various factors on achieved results in a singlecenter study. Materials & Methods. In A.A. Maksimov Clinical Center Hematology Cellular Therapy NI Pirogov Russian National Medical Surgery 260 cHL patients received HDCT combined with auto-HSCT within period from December...
Background. Checkpoint inhibitors contribute to improving the treatment outcomes in patients with relapsed/refractory classical Hodgkin's lymphoma (cHL). The paper describes first generalized experience pembrolizumab-induc-ing cHL immunotherapy Russia. hallmark of study is a long follow-up period. Aim. To retrospectively assess efficacy and safety pem-brolizumab-inducing cHL. Materials & Methods. enrolled 14 patients: 3 men 11 women aged 24-57 years (median 33 years). Pembrolizumab 200...
Background. The national observational program MPN-QoL-2020 was focused on quality of life (QoL) and symptoms in patients with classical Ph-negative myeloproliferative neoplasms (MPNs) the Russian Federation, as well perception disease treatment from patient's physician's perspective. Aim. To evaluate QoL different MPNs using new standardized questionnaires, to assess most common their impact myelofibrosis (MF), polycythemia vera (PV) essential throm-bocythemia (ET), characterize concerns...
The article represents the role of high-dose chemotherapy following autologous hematopoietic stem cell transplantation for Hodgkin lymphoma and summarizes results 10-years’ experience in N.I. Pirogov National Medical Surgical Center. 5-year overall survival was 63 %, progressivefree – 84 % that corresponds with international data. Complete response before main independent prognostic factor efficacy. transplantation.
Aim . To study the efficacy and safety of combined immunochemotherapy according to DHAp protocol + nivolumab in patients with refractory/relapsed classical Hodgkin's lymphoma before autologous hematopoietic stem cell transplantation. Materials methods The consisted 2 phases: 1 st - immunotherapy (2 injections as monotherapy at a dose 240 mg/day 14 days interval); nd (14 after administration nivolumab): 480 on day combination chemotherapy protocol, 4 cycles total. effectiveness therapy was...
Background. High-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplantation (auto-HSCT) is currently regarded as a standard treatment for patients relapsed/refractory classical Hodgkin lymphoma (cHL). The efficacy of correlates the depth antitumor response achieved on pre-transplantation chemotherapy. A combination PD-1 inhibitors new forward-looking approach ensuring higher rate complete responses prior to auto-HSCT well better outcomes in general.
 Aim. To assess...
Classical Hodgkin lymphoma is considered a potentially curable cancer, however, relapsed and refractory disease observed in approximately 10–30% of patients after the first-line treatment. The choice further therapy approach complex because efficacy traditional second-line chemotherapy regimens limited. Immune checkpoint inhibitors (PD-1-inhibitors) are highly effective option relapses classical at present. This article presents comprehensive review studies demonstrating feasibility safety...
BACKGROUND. Over the past years, digital technologies have been increasingly used worldwide for monitoring patient-reported assessment data in real-world clinical practice. Electronic systems allow to automatically assess a patient’s perception of disease and therapy convenient mode, remotely, with obvious savings time resources. AIM. To develop test domestic electronic system health status patients hematologic malignancies based on their quality-of-life data. MATERIALS & METHODS. At...
The risk of developing Hodgkin Lymphoma (HL) is 5 to 26 times higher in HIV-infected patients compared the general population. HL can develop even with moderate immune suppression and treatment antiretroviral medicines. This article reviews current strategy for describes first successful experience high-dose chemotherapy following autologous hematopoietic stem cell transplantation (autoHSCT) an patient at Hematology Department Pirogov National Medical Surgical Center. clinical case...
Currently high-doses chemotherapy (HD-PCT) + autologous hematopoietic stem cells transplantation (auto-HSCT) is the treatment of choice in patients with recurrent and progressive lymphomas. Most quality life (QoL) studies lymphomas received HSCT limited on parameters dynamics assessment early late post-transplant period. Aim this study was to evaluate QoL parameters and their prognostic significance lymphoma before transplantation. 124 (non-Hodgkin – 45 patients, Hodgkin's 79 patients) who...
Aim. Characteristics of thrombocytopenia and finding ways predicting platelet transfusions at autologous hematopoietic stem cell transplantation in patients with hematologic autoimmune diseases. Methods. Thrombocytopenia period after (group I, n=87) hematological II, n=82) diseases was evaluated. Results. It revealed that oncologic count before the on first day it is connected length number transfused platelets units. In diseases, low might be used as a predictor for transfusion risk. Day...
Aim. To assess the efficacy of a long-acting form granulocyte colony-stimulating factor (G-CSF) empegfilgrastim in primary prevention neutropenia patients with advanced stages classical Hodgkin lymphoma (cHL) who received intensive chemotherapy reduced inter-cycle interval under protocol “LKh-Rossiya-1”.
 Materials & Methods. The study enrolled 35 newly diagnosed cHL. All had (IIB X/Е and III/IV) disease. They were treated at NI Pirogov National Medical Surgical Center from March...